[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-562102-105":53,"doc-detail-562102-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","anticoagulation-for-atrial-fibrillation-in-adults-with-advanced-kidney-disease-final-version-september-2025","Anticoagulation for atrial fibrillation in adults with advanced kidney disease - Final version - September 2025","","Clinical practice guideline on anticoagulation for atrial fibrillation in adults with advanced kidney disease, providing final consolidated content dated September 2025. Includes review information, leadership and multidisciplinary working group membership, and acknowledgements to expert Delphi panel contributors. The document outlines executive summary, recommendations, and sections covering background and methods, kidney function estimation for dosing, stroke/bleeding risk scores, treatment options for NVAF thromboprophylaxis, monitoring and follow-up, and additional areas of interest.",{"@graph":63,"@context":119},[64,80,102],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":51,"@type":70,"position":76},"https://docshare.wps.com/template/general/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/anticoagulation-for-atrial-fibrillation-in-adults-with-advanced-kidney-disease-final-version-september-2025/562102/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/anticoagulation-for-atrial-fibrillation-in-adults-with-advanced-kidney-disease-final-version-september-2025/562102.png","ImageObject",442,249,{"name":88,"@type":89},"hdkawk","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-11-02","2026-10-12",true,{"@type":98,"interactionType":99,"userInteractionCount":101},"InteractionCounter",{"@type":100},"ViewAction",8,{"@type":103,"mainEntity":104},"FAQPage",[105,111,115],{"name":106,"@type":107,"acceptedAnswer":108},"Who led and contributed to the development of the guideline?","Question",{"text":109,"@type":110},"The guideline lists co-chairs and a multidisciplinary working group, along with acknowledgements to an expert Delphi panel and feedback from professional organizations.","Answer",{"name":112,"@type":107,"acceptedAnswer":113},"What key clinical topics are covered in the guideline?",{"text":114,"@type":110},"The guideline covers background and methods, kidney function estimates for anticoagulant dosing, stroke and bleeding risk scores, NVAF thromboprophylaxis treatment options, and monitoring and follow-up.",{"name":116,"@type":107,"acceptedAnswer":117},"When is the final version dated, and what is the planned review date?",{"text":118,"@type":110},"The final version is dated September 2025, with a stated review date of September 2028.","https://schema.org",{"og:url":78,"og:type":121,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":123,"canonical":78},"index,follow",{"doc_id":125,"site_id":56},562102,1792093260,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":88,"user_avatar":130,"doc_module":9,"category_id":50,"category_name":51,"doc_title":59,"doc_description":61,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":101,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":136,"language":137,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":138,"faqs":139,"seo_title":140,"seo_description":61,"update_tm":141,"read_time":142},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Clinical Practice Guideline: Anticoagulation for atrial fibrillation in adults with advanced kidney disease  \nFinal version: September 2025  \nReview date: September 2028  \nCo-Chairs:  \nKathrine Parker, Manchester University NHS Foundation trust and University of Manchester Dr Albert Power, University of Bristol and Imperial College London  \nGuideline working group:  \nYvonne Bernes, Sheffield Teaching Hospitals NHS Trust  \nDr Kate Bramham, St Thomas’s Hospital  \nDr Richard Buka, University of Birmingham  \nDr Satarupa Choudhuri, Northern Care Alliance NHS Foundation trust Dr Mark Davies, Cardiff and Vale University Hospital Board  \nDr Maria A Gauci, Bradford Teaching Hospital NHS Foundation Trust  \nLauren Hall, University Hospitals Plymouth NHS Foundation Trust  \nDr John Hartemink, Manchester University NHS Foundation trust Nicola Korn, Norfolk and Norwich University Hospitals NHS Foundation Trust Penny Lewis, University of Manchester  \nProf. Gregory Y.H. Lip, Liverpool John Moores University & Liverpool Heart & Chest Hospital NHS Trust  \nKaty Mills, University Hospitals North Midlands  \nDr Anneka Mitchell, University Hospitals Plymouth NHS Trust  \nDr Lara Roberts, Kings College Hospital NHS Foundation Trust  \nHuw Rowswell, University Hospitals Plymouth NHS Trust  \nDr Hannah Stacey, Mid and South Essex NHS Foundation trust  \nKatherine Stirling, Leeds Teaching NHS Foundation Trust  \nProf. Jecko Thachil, Manchester University NHS Foundation Trust and University of Manchester Dr Honey Thomas, Northumbria Healthcare NHS Foundation Trust  \nFang Feng Ting, Watford General Hospital  \nDr Jung Tsang, Bodey Medical Practice and University of Manchester Isaac Tseng, Oxford University Hospitals  \nDr Andrew Turley, South Tees NHS Foundation Trust  \nAlan Hancock, Patient representative  \nDonna Lewis, Patient representative  \nEd Jenkinson, Patient representative  \nAlan Craig*, Patient representative  \nAcknowledgements  \nAcknowledgements to expert Delphi panel members who provided their expertise in the development of the consensus statements used in this guideline:  \nProf. Raza Alikhan, University Hospital Wales Sotiris Antoniou, Barts Heart Centre  \nJoanne Bateman, Countess of Chester Hospital Dr Kate Bramham, R St Thomas’s Hospital Dr Richard Buka, University of Birmingham  \nProf. John Camm, St. George's University of London Dr Alexander Cohen, Guy's and St Thomas' Hospital Prof. Andrew Davenport, University College, London Prof. Charles Ferro, University Hospitals Birmingham  \nProf Philip Kalra, Salford Royal NHS Foundation Trust & University of Manchester  \nProf Gregory Y.H. Lip, Liverpool John Moores University & Liverpool Heart & Chest Hospital NHS Trust  \nDr Albert Power, North Bristol NHS Trust  \nDr Lara Roberts, Kings College Hospital NHS Foundation Trust Dr Susie Shapiro, Oxford University Hospitals  \nKatherine Stirling, Leeds Teaching NHS Foundation Trust Dr David Sutton, University Hospitals of North Midlands Dr Will Thomas, Cambridge University Hospitals  \nIsaac Tseng, Oxford University Hospitals  \nDr Honey Thomas, Northumbria Healthcare NHS Foundation Trust Dr Andrew Turley, South Tees NHS Foundation Trust  \nProf. Stephen Wheatcroft, Leeds Teaching NHS Foundation Trust & University of Leeds  \nKathrine Parker was supported by the National Institute for Health Research (HEE/ NIHR ICA Programme Clinical Doctoral Research Fellowship, Miss Kathrine Parker, NIHR300545) to undertake a programme of research which forms the basis for this guideline. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.  \nProf. Sandip Mitra supervised Kathrine Parker undertaking this work.  \n*Alan Craig was one of the patients who kindly contributed to the work that forms part of this guideline but sadly passed away before the guideline was complete. Alan was always enthusiastic about improving kidney care for all but w","cbCaifObhqdzIzkg","https://ap.wps.com/l/cbCaifObhqdzIzkg","pdf",1254057,93,"English","# Acknowledgements\n# Contents\n# Executive Summary\n# Summary of recommendations\n# Section 1: Background, aims and concise methods\n# Section 2: Kidney function estimates for anticoagulant dosing\n# Section 3: The use of risk scores for stroke and bleeding assessment\n# Section 4: Treatment options for NVAF thromboprophylaxis\n# Section 5: Monitoring and follow up\n# Section 6: Areas of interest\n# Section 7: Lay executive summary","[{\"question\":\"Who led and contributed to the development of the guideline?\",\"answer\":\"The guideline lists co-chairs and a multidisciplinary working group, along with acknowledgements to an expert Delphi panel and feedback from professional organizations.\"},{\"question\":\"What key clinical topics are covered in the guideline?\",\"answer\":\"The guideline covers background and methods, kidney function estimates for anticoagulant dosing, stroke and bleeding risk scores, NVAF thromboprophylaxis treatment options, and monitoring and follow-up.\"},{\"question\":\"When is the final version dated, and what is the planned review date?\",\"answer\":\"The final version is dated September 2025, with a stated review date of September 2028.\"}]","Anticoagulation for atrial fibrillation in adults with advanced kidney disease - Final version - September 2025 | PDF",1791807731,33]